LivaNova (LIVN)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$91.14-3.24%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · LIVN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 17.0% |
| Our one-year growth estimate | diamond | 7.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Usually moved in the opposite direction.
Price observations: 365 days
Most sensitive to the broad stock market and long-term interest rates.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 9.8 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 42 industry peers · Company calendar date is not available
LIVN — President transition
Dated 2026-01-14
Chief Legal Officer — Michael Hutchinson: The Chief Legal Officer is resigning to pursue another opportunity, which is a standard executive departure without indication of cause or distress.
Why it matters: The FDA cleared aura6000 for sleep apnea, and LivaNova is building an OSA business. Early sales and implant counts can show whether the launch is gaining ground.
Supportive ifA company update reports aura6000 sales and more implants after launch. It also reports continued gains in OSA patient response.
Worry ifA company update reports no aura6000 sales, falling implant counts, or a pause in the OSA launch.
Why it matters: LivaNova raised its full-year growth goal to 8%–9%. Q3 results test whether growth stays near that pace.
Worry ifQ3 revenue growth, excluding currency effects, is below 8%. Or, management cuts its 2026 growth guide to below 8%.
Less concerning ifQ3 constant-currency revenue growth is at least 8%, and the 2026 guide stays at 8%–9%.
Why it matters: LivaNova cut its cash flow range to $140 million–$160 million as it invests in capacity and systems. The year-end result will show the cost of that spending.
Worry ifFull-year adjusted free cash flow is below $140 million, or the company cuts its guide below $140 million.
Less concerning ifFull-year adjusted free cash flow is at least $140 million and within the $140 million–$160 million guide.
Why it matters: Q2 adjusted EPS rose to $1.26, and the full-year guide is now $4.30–$4.40. A weaker Q3 could put that goal at risk.
Worry ifQ3 adjusted diluted EPS is below $1.26, or the full-year guide falls below $4.30.
Less concerning ifQ3 adjusted diluted EPS is at least $1.26, and the full-year guide stays at $4.30–$4.40 or rises.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$115 on $10,000 · ±1.1% | How much price usually moves either way. |
| Bad day | $297 loss on $10,000 · 3.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,889 loss on $10,000 · 18.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.